CASI

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) is a biopharmaceutical company founded in 1991 and originally incorporated as EntreMed, Inc. before changing its name in June 2014. Based in Rockville, Maryland, the company has evolved from its early incarnation into a specialized biopharmaceutical firm focused on developing and commercializing cancer treatments, particularly for the Chinese market. The company went public in 1996 and has since built a portfolio of oncology therapeutics, with a primary focus on blood cancers and solid tumors. CASI operates internationally, with significant commercial and development activities in China, the United States, and other global markets.